SCHEDULE 13G/A: Venrock Healthcare Capital Partners Amends Aquestive Therapeutics Stake, Reports 2.9% Beneficial Ownership

Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 2.9% in Aquestive Therapeutics, Inc. as of December 31, 2024.

Summary

• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
• The reporting group, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, collectively beneficially own 2,629,786 shares of Aquestive Therapeutics, Inc. common stock.
• This aggregate amount represents 2.9% of Aquestive Therapeutics' common stock outstanding as of December 31, 2024.
• The percentage is based on 91,178,193 shares of common stock outstanding as of November 1, 2024, as reported by Aquestive Therapeutics in its Form 10-Q.
• The reporting persons hold shared voting and shared dispositive power over all 2,629,786 shares.
• The securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a significant investor group has reduced its stake below the 5% threshold, which could imply a decrease in confidence or a strategic divestment, although the document itself is a neutral compliance filing.

Negatives

• The filing indicates a reduction in the beneficial ownership stake by the Venrock Healthcare Capital Partners group to below the 5% threshold, which could be interpreted as a decrease in conviction or a strategic divestment by a significant investor.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor group in a publicly traded biotechnology or pharmaceutical company, Aquestive Therapeutics, Inc. Such filings provide transparency regarding significant shareholder positions, which can influence market perception of a company's investor base.

Stakeholder Impact

• Shareholders: The reduction in stake by a significant institutional investor group may be perceived as a negative signal regarding the company's future prospects or the investor's confidence, potentially influencing other investors' decisions.

Key Dates

Keywords

Aquestive Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Equity Stake